Pricing Log in Create free account
Sunday 18 October 2026 Export XFOR’s income statement to Excel — free account

X4 Pharmaceuticals, Inc.

XFOR Healthcare Biotechnology

In the quarter to June 2026, revenue grew 346.3%, EPS grew 96.3%, free cash flow grew 13.8% and total debt rose 1.21%, each against the same quarter a year earlier.

2.59 0.05 −1.89%
Market cap
$261.8M
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
n/a
Altman Z
−1.78
Beneish M
8.05
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.46
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — 1 1 — 2 — 1
Insider Ownership 40.59%

Capital & Financial Ratios $m

Market Cap 261.75
Revenue 15.85
Net Income (90.14)
Free Cash Flow (88.74)
Net Debt (131.21)
Current Ratio 11.30 (at or above 1.5: strong)
Debt/Equity 0.49 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (5.07) (negative: loss-making)
P/S ratio 20.65 (above 10: high)
P/B ratio 2.11
Past 5Y EPS Growth —
This Y EPS Growth 65.13% (at or above 15%: strong)
Next Y EPS Growth (7.98%) (below 0%: weak)
Next Y revenue growth (54.49%) (below 0%: weak)
Next 5Y EPS Growth 23.57% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 62.99%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 114 102 253 208
Receivables 1 2 1 2
Inventory — 3 4 6
Other — — — —
122 112 262 219
2023 2024 2025 Q'26
Payables 9 9 6 4
ST’ Debt — — — —
Other — — — —
23 33 26 19

Compound Annual Growth %

10y 5y 3y
Sales — — 115.68%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 20.67% 36.00%

Revenue $m

Mar Jun Sep Dec Year
’26 3 9 — — —
’25 29 2 2 3 35
’24 — 1 1 1 3
’20 3 — — — 3
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (20) (21) — — —
’25 (12) (30) (28) (16) (86)
’24 (34) (30) (34) (33) (131)
’23 (27) (21) (21) (28) (97)
’22 (20) (18) (19) (19) (77)
’21 (18) (19) (14) (19) (71)
’20 (16) (11) (14) (18) (59)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (20) (26) — — —
’25 (15) (30) (28) (16) (89)
’24 (34) 68 (34) (33) (33)
’23 (27) (21) (21) (28) (97)
’22 (20) (19) (19) (19) (77)
’21 (19) (19) (14) (19) (72)
’20 (16) (11) (15) (18) (60)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.16) (0.13) — — —
’25 0.04 (3.47) (0.69) (0.22) (1.87)
’24 (7.81) 13.51 (5.41) (6.01) (5.71)
’23 (4.80) (9.91) (0.30) (3.00) (17.12)
’22 (21.62) (18.02) (7.81) (8.71) (45.65)
’21 (39.04) (22.22) (22.82) (37.24) (119.82)
’20 (16.82) (22.82) (26.13) (27.33) (92.79)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — 1,872.00 207.00 280.80 161.40 54.00 19.50 17.16 7.83 1.35

Analyst estimates 2026–2028

Powerpack
High — 3,550.68 5,164.92 717.90 334.80 321.12 78.90 77.25 48.00 24.45
People
People Employees 39 40 15 58 72 83 70 93 143 45
Revenue/emp, $m 0.00 0.00 0.23 0.00 0.04 0.00 0.00 0.00 0.02 0.78
Income, $m
Income, $m Revenue — — 4 — 3 — — — 3 35
Gross margin, % — — 100.00 — 100.00 — — — 68.83 83.60
EBT (23) (22) (33) (53) (62) (89) (94) (101) (37) (79)
EBT margin, % 0.00 0.00 (951.00) 0.00 (2,066.10) 0.00 0.00 0.00 (1,452.48) (225.44)
Net income (23) (22) (33) (53) (62) (89) (94) (101) (37) (79)
Depreciation 0 0 0 0 0 10 1 0 1 1
Per share, $
Per share, $ Revenue 0.00 0.00 228.76 0.00 4.49 0.00 0.00 0.00 0.38 0.83
Earnings (8,059.58) (1,442.10) (2,177.67) (139.04) (92.79) (119.82) (45.65) (17.12) (5.71) (1.87)
Cash flow (7,461.72) (1,392.88) (1,661.44) (125.18) (87.97) (82.70) (36.45) (16.28) (19.53) (2.02)
Capex (25.17) (24.71) (2.22) 2.15 (2.04) (0.72) (0.05) (0.01) 14.57 (0.07)
Free cash flow (7,486.90) (1,417.58) (1,663.66) (123.02) (90.01) (83.41) (36.50) (16.29) (4.96) (2.10)
Book value (5,766.90) 3,837.06 (811.18) 336.60 108.88 75.12 35.01 8.62 3.30 4.40
Shares, m 0 0 0 0 1 1 2 6 7 42
Valuation, ×
Valuation, × P/E — — 0.00 — 0.00 — — — 0.00 0.00
P/S — — 0.00 — 0.00 — — — 26.56 4.82
P/B — — 0.00 — 1.77 — — — 6.66 0.91
EV/Sales — — 0.00 — 0.00 — — — 21.90 (0.19)
EV/FCF — — (0.32) — (1.40) — — — (4.64) (0.42)
Cash, $m
Cash, $m Operating cash flow (22) (21) (25) (48) (59) (71) (77) (97) (131) (86)
Capex 0 0 0 1 (1) (1) 0 0 98 (3)
Free cash flow (22) (22) (25) (47) (60) (72) (77) (97) (33) (89)
Balance, $m
Balance, $m Working capital (6) 69 1 120 71 74 106 99 79 236
Total debt 10 10 10 21 33 34 34 55 75 76
Net debt 7 (67) 2 (105) (46) (48) (88) (60) (27) (177)
Shareholders’ equity (17) 59 (12) 129 73 64 74 51 22 186
Returns, %
Returns, % ROA (268.79) (56.26) (79.62) (62.59) (43.82) (85.52) (70.69) (66.81) (25.50) (36.25)
ROIC 0.00 0.00 0.00 (134.47) (137.23) (321.23) 0.00 0.00 0.00 (566.65)
ROE 50.61 (2,330.44) 395.09 (204.85) (61.51) (149.61) (139.26) (161.67) (102.26) (75.99)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

X4 Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
EYPT EyePoint, Inc. $270.7M — (loss-making) — (loss-making) −90.49% (below 0%: shrinking) n/m +0.41% (above 0%: growing) 100.00% (19,207.10%) Compare
PALI Palisade Bio, Inc. $268.4M 2.2× — (loss-making) +19,900.00% (above 0%: growing) n/m −318.44% (below 0%: shrinking) 100.00% (2,339.60%) Compare
ABEO Abeona Therapeutics Inc. $265.9M — (loss-making) — (loss-making) +225.14% (above 0%: growing) n/m +17.11% (above 0%: growing) 63.30% (119.97%) Compare
PRLD Prelude Therapeutics Incorporated $265.0M — (loss-making) — (loss-making) +42.60% (above 0%: growing) n/m +40.32% (above 0%: growing) 100.00% (270.93%) Compare
CABA Cabaletta Bio, Inc. $262.8M — (loss-making) — — n/m −35.72% (below 0%: shrinking) 0.00% 0.00% Compare
XFOR X4 Pharmaceuticals, Inc. $261.8M — (loss-making) — (loss-making) +346.33% (above 0%: growing) n/m +13.76% (above 0%: growing) 81.64% (186.13%)
RCKT Rocket Pharmaceuticals, Inc. $259.1M — (loss-making) — — n/m +19.16% (above 0%: growing) 0.00% 0.00% Compare
VNDA Vanda Pharmaceuticals Inc. $256.4M — (loss-making) — (loss-making) −3.92% (below 0%: shrinking) n/m −101.02% (below 0%: shrinking) 92.95% (126.28%) Compare
IKT Inhibikase Therapeutics, Inc. $255.4M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −123.23% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $263.9M — — +19.34% — −17.65% 78.13% (123.12%)

All 614 Biotechnology stocks →

X4 Pharmaceuticals, Inc. (XFOR) key facts

  • X4 Pharmaceuticals, Inc. (XFOR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, XFOR traded at $2.59, a market capitalization of $261.8 million.
  • Return on equity was −76.0% and debt-to-equity 0.49.
  • Its Altman Z-score is −1.78 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

X4 Pharmaceuticals, Inc. (XFOR) Latest News

29 Apr

Impact 5 ·
stockrow.com/XFOR · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com